<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880356</url>
  </required_header>
  <id_info>
    <org_study_id>MaNeNeND</org_study_id>
    <nct_id>NCT04880356</nct_id>
  </id_info>
  <brief_title>Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.</brief_title>
  <official_title>Clinical, Instrumental and Laboratory Data Collection of Subjects With Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      General aim of the study is the improvement of the clinical knowledge of ultra-rare inherited&#xD;
      metabolic and degenerative neurological diseases (prevalence less than 5:100,000) in&#xD;
      adulthood through the systematic longitudinal collection of clinical, laboratory and&#xD;
      instrumental data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study provides a collection of retrospective data from adult patients with ultra-rare&#xD;
      inherited neurological diseases followed at &quot;Carlo Besta&quot; Neurological Institute from 1st&#xD;
      January 2004 until March 2021. Further, prospective data will be collected starting from&#xD;
      March 2021 (date of protocol approval) and spanning the next ten years. Normal clinical&#xD;
      practice will be followed for collection of the prospective data. Follow-up assessment will&#xD;
      be performed at least once a year to evaluate the disease course. Based on their clinical&#xD;
      manifestations, patients will be assessed by using quantitative functional tests (clinimetric&#xD;
      tests such as Timed Up and Go Test) and traditional ordinal scales (such as the scale for the&#xD;
      assessment and rating of ataxia (SARA). Moreover, a varying of laboratory and instrumental&#xD;
      tests (e.g., neuroimaging, neurophysiological investigations, etc.) will be used according to&#xD;
      clinical practice in selected patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Verbal (letter) fluency</measure>
    <time_frame>10 years</time_frame>
    <description>Repeated Montreal Cognitive Assessment (MoCA) letter F fluency subtest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stance and gait performances [Time Frame: 10 years] Stance and gait performances</measure>
    <time_frame>10 years</time_frame>
    <description>Repeated SARA (Scale for the Assessment and Rating Ataxia) stance subtask, ambulation index (AI) and Timed Up and Go (TUG) test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upper limb motor function</measure>
    <time_frame>10 years</time_frame>
    <description>Repeated ONLS (Overall Neuropathy Limitation Scale) arm scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Swallowing function (dysphagia)</measure>
    <time_frame>10 years</time_frame>
    <description>Repeated NP-C mDRS (Niemann-Pick type C modified disability rating scale) swallowing scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Speech function (dysarthria)</measure>
    <time_frame>10 years</time_frame>
    <description>Repeated NP-C mDRS language scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bladder function</measure>
    <time_frame>10 years</time_frame>
    <description>Repeated AADS (Adult Adrenoleukodystrophy Disability Score) Bladder function scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep</measure>
    <time_frame>10 years</time_frame>
    <description>Repeated assessment of presence or absence of sleep disturbances</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>10 years</time_frame>
    <description>Repeated EuroQol-5D-5L (EQ-5D-5L) questionnaire</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Inherited Disease</condition>
  <condition>Rare Diseases</condition>
  <condition>Metabolic Disease</condition>
  <condition>Undiagnosed Disease</condition>
  <condition>Neurologic Disorder</condition>
  <condition>Neuro-Degenerative Disease</condition>
  <arm_group>
    <arm_group_label>Retrospective study</arm_group_label>
    <description>collection of retrospective data from adult patients with ultra-rare inherited neurological diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective study</arm_group_label>
    <description>prospective data will be collected starting from March 2021 (date of protocol approval) and spanning the next ten years</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>collection of data</intervention_name>
    <description>collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases</description>
    <arm_group_label>Prospective study</arm_group_label>
    <arm_group_label>Retrospective study</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with ultra-rare inherited degenerative and metabolic neurological diseases&#xD;
&#xD;
        Adults with undiagnosed neurological diseases (when supposed to be inherited)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Subjects with ultra-rare inherited degenerative and metabolic neurological diseases&#xD;
&#xD;
          -  Subjects with undiagnosed neurological diseases (when supposed to be inherited)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ettore Salsano, MD</last_name>
    <phone>+39022394</phone>
    <phone_ext>3001</phone_ext>
    <email>ettore.salsano@istituto-besta.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renato Mantegazza, MD</last_name>
    <phone>+39022394</phone>
    <phone_ext>2321</phone_ext>
    <email>crc@istituto-besta.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Mauro, MD</last_name>
      <phone>+39022394</phone>
      <phone_ext>2388</phone_ext>
      <email>elena.mauro@istituto-besta.it</email>
    </contact>
    <investigator>
      <last_name>Ettore Salsano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukodystrophies,</keyword>
  <keyword>Adrenoleukodystrophy,</keyword>
  <keyword>Metachromatic leukodystrophy,</keyword>
  <keyword>Krabbe disease,</keyword>
  <keyword>Vanishing White Matter Syndrome,</keyword>
  <keyword>Alexander disease,</keyword>
  <keyword>Hereditary Leukodystrophy with Spheroids (CSF1R-related HLDS),</keyword>
  <keyword>Nasu-Hakola disease (TREM2- and TYROBP-related disease)</keyword>
  <keyword>Leukoencephalopathy, progressive, with ovarian failure (LKENP, AARS2-related),</keyword>
  <keyword>Pelizaeus-Merzbacher disease,</keyword>
  <keyword>Pelizaeus-Merzbacher-like disease,</keyword>
  <keyword>Hypomyelinating leukodystrophies,</keyword>
  <keyword>Leukodystrophies with calcifications and cysts (LCC),</keyword>
  <keyword>Leukoencephalopathy with ataxia disease (LKPAT, CLCN2-related),</keyword>
  <keyword>L-2-Hydroxyglutaric aciduria,</keyword>
  <keyword>Polyglucosan bodies disease,</keyword>
  <keyword>Methylmalonic acidemia with homocystinuria,</keyword>
  <keyword>Niemann-pick type C,</keyword>
  <keyword>Fahr's disease,</keyword>
  <keyword>Wilson's disease,</keyword>
  <keyword>Cerebrotendinous Xanthomatosis,</keyword>
  <keyword>Sphingolipidoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Rare Diseases</mesh_term>
    <mesh_term>Undiagnosed Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

